Home / Pharmaceutical company intelligence
Pharmaceutical company intelligence

Seraph Pharmaceutical

Pharmaceutical manufacturer · Islamabad · Pakistan

Islamabad-based pharmaceutical manufacturer producing general and cephalosporin dosage forms including tablets, capsules, topicals and injectables.

Sourced corporate profile Corporate identity fields are source-tracked; portfolio, price and competitor intelligence remains independently calculated by MedInfoBase.
Official website ↗
ShareSend this page
Evidence & freshness

What is sourced, and how recent is it?

Public-source corporate details
Latest regulatory-source observation23 Sep 2026Newest linked source record observed by MedInfoBase
Latest portfolio source check27 Aug 2026Latest source-check date across this published portfolio
Latest effective price date1 Jul 2024Newest effective date among published current price records
Corporate profile evidence3 sourcesCorporate source details checked 16 Aug 2026

Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.

Regulatory & corporate identity

Company profile

Public-source corporate details
Company type
Pharmaceutical manufacturer
Address
Plot No. 210, Industrial Triangle, Kahuta Road, Islamabad, Pakistan
Phone
+92 51 4493210
Corporate source details checked
16 Aug 2026
Corporate profile completeness
88%
DRAP manufacturing licenceAs published by the DRAP Licensing Division. DRAP issues this list for stakeholder review and states it is not a reference for litigation, claims or citation.
Formulation 000860 Seraph Pharmaceutical. · Islamabad
Source-linked licence identifiersShown as recorded in linked source rows; not a claim of current validity.
DML 000860 103 linked products · source seen 23 Sep 2026 View source ↗
Corporate profile source ledger Logo Source Url source ↗ Profile Source Url source ↗
Location intelligence

Company location

Google Maps
Location recorded

A sourced company location is recorded. Use the map link below for directions.

Open in Google Maps ↗
Intelligence snapshot

Portfolio at a glance

Not sales data · published MedInfoBase database view
Rx109public portfolio records represented
REG74unique registrations represented
IDX103indexed MedInfoBase presentations
SRC5additional source-observed presentations
R+1registry-only registrations
VER0registry-verified exact registrations
PKR103current validated price records
G35generic molecules in indexed catalogue
DF10dosage-form groups
TA7therapeutic areas
How to read these counts

RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.

PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.

IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.

Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.

Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.

Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.

Data coverage

How complete is this profile?

Current price coverage94%
public portfolio presentations with a validated current price
Official-source coverage100%
products linked back to a source record
Unit-price parse coverage100%
priced packs safely normalized per unit
Comparable-market coverage94%
products with at least one like-for-like comparator
Therapeutic classification100%
products assigned to a broad therapeutic area
Visual intelligence

Downloadable company intelligence charts

Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.

Shareable intelligence

Therapeutic Portfolio Mix

Shows where the company portfolio is concentrated across broad therapeutic areas.

Therapeutic Portfolio MixSeraph PharmaceuticalShare of current product presentations by broad therapeutic areaMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/seraph-pharmaceuticalGenerated 23 Sep 2026Anti-infectives57 · 55%CNS & mental health29 · 28%Dermatology5 · 5%Gastrointestinal & hepatology5 · 5%Oncology & immunology4 · 4%Cardiovascular2 · 2%Other specialty1 · 1%Percentages are based on current product presentations in the MedInfoBase company portfolio.

Portfolio distribution, not sales or market-share data.

Shareable intelligence

Dosage Form Portfolio

Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.

Dosage Form PortfolioSeraph PharmaceuticalDistribution of current product presentations by normalized dosage formMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/seraph-pharmaceuticalGenerated 23 Sep 2026103presentationsTablet48 · 47%Injection30 · 29%Cream7 · 7%Capsule6 · 6%Lotion3 · 3%Solution3 · 3%Other forms6 · 6%Dosage-form wording is normalized for intelligence display; original source wording remains preserved in product records.

Counts are product presentations, not production or sales volumes.

Shareable intelligence

Equivalent Price Position

Shows whether safely comparable products are below, near or above the peer median unit price.

Equivalent Price PositionSeraph PharmaceuticalCurrent company products compared with like-for-like equivalent medicines using normalized unit pricesMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/seraph-pharmaceuticalGenerated 23 Sep 202697comparable productsBelow peer median56 · 58%Near peer median36 · 37%Above peer median5 · 5%Company median price position-6.9%Lowest-price equivalents9Method: same generic + stated strength + dosage form + compatible unit basis; pack prices normalized per unit.

This is price-position intelligence, not sales, demand or market-share data.

Shareable intelligence

Closest Portfolio Competitors

Highlights other manufacturers with the greatest generic overlap with this company portfolio.

Closest Portfolio CompetitorsSeraph PharmaceuticalCompanies with the largest number of shared generic medicines in the MedInfoBase databaseMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/seraph-pharmaceuticalGenerated 23 Sep 2026Nabiqasim Industries (Pvt) Ltd.,26 shared74% overlapPharmasol (Pvt) Ltd.26 shared74% overlapCCL Pharmaceuticals (Pvt.) Limited24 shared69% overlapBio-Labs(Pvt) Ltd23 shared66% overlapHIGH-Q Pharmaceuticals23 shared66% overlapMediate Pharmaceutical Pvt Ltd22 shared63% overlapPortfolio overlap measures shared generics only; it is not a measure of market share, affiliation or sales competition.

Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.

Portfolio intelligence

Therapeutic areas

Broad portfolio view

High-level clinical areas represented by this company’s current MedInfoBase portfolio.

Anti-infectives57 products · 55%
CNS & mental health29 products · 28%
Dermatology5 products · 5%
Gastrointestinal & hepatology5 products · 5%
Oncology & immunology4 products · 4%
Cardiovascular2 products · 2%
Other specialty1 products · 1%
Pharmacological detail

Drug classes

More specific view

More specific classes derived from the canonical generic and preserved curated classifications.

Third-generation cephalosporins19 products · 18%
Antipsychotics12 products · 12%
Antiepileptics12 products · 12%
Macrolide antibacterials8 products · 8%
Fluoroquinolone antibacterials6 products · 6%
Antifungals5 products · 5%
Antipsoriatic medicines5 products · 5%
Antiparasitic medicines5 products · 5%
Formulation footprint

Dosage forms

Tablet48 products
Injection30 products
Cream7 products
Capsule6 products
Lotion3 products
Solution3 products
Gel2 products
Suspension2 products
Infusion1 products
Ointment1 products
How MedInfoBase classifies the portfolio

MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.

Portfolio leaders

Deepest brand families

Ranked by registered presentations · not sales
#1 DroncefCeftriaxone 12presentations 1 g, 2 g, 250 mg, 500 mg · Injection #2 LevaceLevetiracetam 10presentations 100 mg, 100 mg/mL, 250 mg, 500 mg · Injection, Solution, Tablet #3 OrisRisperidone 6presentations 1 mg, 2 mg, 3 mg, 4 mg · Tablet #4 CequelQuetiapine 5presentations 100 mg, 25 mg, 300 mg · Tablet #5 CartrialCalcipotriol 4presentations 0.005%, 0.05 mg, 0.05 mg/g · Cream #6 Zyban 150mg SRBupropion 4presentations 150 mg · Tablet
Price intelligence

Unit-price positioning vs equivalent products

Same generic + strength + form + unit basis
Below market median5658% of comparable products
Near market median36within ±5% of median
Above market median55% of comparable products
Lowest-price equivalents9ties included
Company median price position -6.9% relative to the median unit price of like-for-like equivalent products.
Most competitively positioned examplesProducts with at least 3 market comparators
Zyban 300 mgBupropion · Sustained-release tablet · 2x10's PKR 47.07/tablet-47.3% vs market median Sthrin 5%Permethrin · Cream · 30gm PKR 2.48/g-36.5% vs market median Actarin 20 mg/gMiconazole · Gel · 20 gm PKR 6.78/g-22.3% vs market median Sephrix B 0.5 mgEntecavir · Tablet · 3x10's PKR 280.20/tablet-21.3% vs market median Icunem 1 gMeropenem · Injection · 1's PKR 3,188.94/vial/unit-19.5% vs market median
How MedInfoBase calculates price position

Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.

Competitive landscape

Portfolio overlap

Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.

Nabiqasim Industries (Pvt) Ltd.,365 products · 118 generics 26shared generics Pharmasol (Pvt) Ltd.257 products · 102 generics 26shared generics CCL Pharmaceuticals (Pvt.) Limited249 products · 99 generics 24shared generics Bio-Labs(Pvt) Ltd236 products · 82 generics 23shared generics HIGH-Q Pharmaceuticals215 products · 61 generics 23shared generics Mediate Pharmaceutical Pvt Ltd236 products · 90 generics 22shared generics
Regulatory & price activity

Observed database signals

Indexed registration numbers71Distinct registrations among indexed, published, presentation-validated products only
Verified price observations103
Products with a verified price103
Products with multiple price observations0
Source records with multiple versions102
Latest portfolio source check27 Aug 2026
Latest effective price date1 Jul 2024
Latest source observation23 Sep 2026

These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.

Company medicine portfolio

Medicine portfolio

74 unique registration(s) · 103 indexed presentation(s) · 5 additional source-observed presentation(s) · 1 registry-only registration(s)

This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.

Reset
BrandGenericStrengthFormPackRegistrationSource-listed priceUnit pricePrice position
Actarin Miconazole 20 mg/g Gel 20 gm 103748 PKR 135.54 PKR 6.78/g 22% below median
Anbrez Anastrozole 1 mg Tablet 3x10's 093358 PKR 9,901.11 PKR 330.04/tablet Near median
Azikem Azithromycin 250 mg Tablet 1x6's 094387 PKR 269.05 PKR 44.84/tablet Near median
Azikem Azithromycin 500 mg Tablet 1x6's 094388 PKR 493.26 PKR 82.21/tablet Near median
Azipar Azithromycin 250 mg Capsule 1x6's 093357 PKR 274.43 PKR 45.74/capsule 8% below median
Azipar Azithromycin 250 mg Capsule 1x10's 093357 PKR 435.05 PKR 43.51/capsule 12% below median
Canzo Fluconazole 150 mg Capsule 1's 087364 PKR 247.53 PKR 247.53/capsule 6% below median
Cartrial Calcipotriol 0.05 mg Cream 15 gm 092340 PKR 658.94 PKR 43.93/g No comparator
Cartrial Calcipotriol 0.005% Cream 5 gm 092340 PKR 220.27 PKR 44.05/g Near median
Cartrial Calcipotriol 0.05 mg/g Cream 60 gm 092340 PKR 2,503.93 PKR 41.73/g No comparator
Cartrial Calcipotriol 0.005% Cream 30 gm 092340 PKR 1,344.22 PKR 44.81/g Near median
Cartrial Plus Calcipotriol + Betamethasone 0.05 mg + 0.5 mg Ointment 15 gm 092341 PKR 706.00 PKR 47.07/g No comparator
Cequel Quetiapine 25 mg Tablet 3x10's 085273 PKR 626.57 PKR 20.89/tablet Near median
Cequel Quetiapine 25 mg Tablet 1x10's 085273 PKR 208.86 PKR 20.89/tablet Near median
Cequel Quetiapine 25 mg Tablet 2x10's 085273 PKR 417.70 PKR 20.89/tablet Near median
Cequel Quetiapine 100 mg Tablet 1x10's 085274 PKR 626.57 PKR 62.66/tablet 16% below median
Cequel Quetiapine 300 mg Tablet 1x10's 094149 PKR 1,253.11 PKR 125.31/tablet 8% below median
Cequel 150mg XR Quetiapine 150 mg Extended-release tablet 1x10's 094385 PKR 812.43 PKR 81.24/tablet Near median
Certum Ceftazidime 250 mg Injection 1's 086237 PKR 148.36 PKR 148.36/vial/unit 7% below median
Certum Ceftazidime 500 mg Injection 1's 086238 PKR 213.64 PKR 213.64/vial/unit 12% below median
Certum Ceftazidime 1 g Injection 1's 086239 PKR 407.97 PKR 407.97/vial/unit 12% below median
Ciptec Ciprofloxacin 250 mg Tablet 1x10's 093355 PKR 233.17 PKR 23.32/tablet 8% below median
Ciptec Ciprofloxacin 500 mg Tablet 1x10's 093356 PKR 385.64 PKR 38.56/tablet 10% below median
Czartan Losartan 50 mg Tablet 2x10's 094150 PKR 358.73 PKR 17.94/tablet 14% below median
Czartan Plus 50/12.5mg Losartan + Hydrochlorothiazide 50 mg + 12.5 mg Tablet 2x10's 094137 PKR 538.10 PKR 26.91/tablet 13% below median
DSource observed Cholecalciferol 5 mg/1 mL Injection 1's 103718Official source ↗ No indexed price — —
DSource observed Cholecalciferol 5 mg/1 mL Injection 5's 103718Official source ↗ No indexed price — —
DSource observed Cholecalciferol 5 mg/1 mL Injection 1's 103718Official source ↗ No indexed price — —
Droncef Ceftriaxone 250 mg IM injection 1's 087745 PKR 181.16 PKR 181.16/vial/unit 8% below median
Droncef Ceftriaxone 500 mg IM injection 1's 087746 PKR 304.92 PKR 304.92/vial/unit 8% below median
Droncef Ceftriaxone 1 g Injection 25's 087747 PKR 13,559.04 PKR 542.36/vial/unit 10% below median
Droncef Ceftriaxone 1 g Injection 1's 087747 PKR 575.77 PKR 575.77/vial/unit Near median
Droncef Ceftriaxone 1 g Injection 10's 087747 PKR 5,423.83 PKR 542.38/vial/unit 10% below median
Droncef Ceftriaxone 2 g Injection 25's 087748 PKR 19,362.72 PKR 774.51/vial/unit Near median
Droncef Ceftriaxone 2 g Injection 1's 087748 PKR 807.15 PKR 807.15/vial/unit Near median
Droncef Ceftriaxone 2 g Injection 10's 087748 PKR 7,744.66 PKR 774.47/vial/unit Near median
Droncef Ceftriaxone 500 mg IV injection 25's 103746 PKR 6,497.04 PKR 259.88/vial/unit 17% below median
Droncef Ceftriaxone 500 mg IV injection 1's 103746 PKR 271.06 PKR 271.06/vial/unit 14% below median
Droncef Ceftriaxone 500 mg IV injection 10's 103746 PKR 2,597.96 PKR 259.80/vial/unit 17% below median
Droncef Ceftriaxone 250 mg IV injection 1's 103747 PKR 161.04 PKR 161.04/vial/unit 14% below median
Empro 40mg InjectionRegistry verified Esomeprazole as sodium — — — 110932Official source ↗ No indexed price — —
Eniqa Eflornithine 11.5% Cream 15 gm 092349 PKR 1,835.60 PKR 122.37/g No comparator
Fascar Clarithromycin 250 mg Tablet 1x10's 094145 PKR 430.48 PKR 43.05/tablet 10% below median
Fascar Clarithromycin 500 mg Tablet 1x10's 094146 PKR 717.48 PKR 71.75/tablet 15% below median
Fascar Clarithromycin 500 mg Extended-release tablet 1x5's 094147 PKR 371.29 PKR 74.26/tablet 10% below median
Fascar XL Fascar XL Clarithromycin 500 mg Extended-release tablet 1x10's 094147 PKR 692.66 PKR 69.27/tablet 16% below median
Furoxim Cefuroxime 250 mg IM/IV injection 1's 101843 PKR 44.64 PKR 44.64/vial/unit No comparator
Icunem Meropenem 500 mg Injection 1's 103719 PKR 1,755.39 PKR 1,755.39/vial/unit 16% below median
Icunem Meropenem 1 g Injection 1's 103720 PKR 3,188.94 PKR 3,188.94/vial/unit 20% below median
Kefone Cefazolin 250 mg Injection 1's 086245 PKR 71.74 PKR 71.74/vial/unit 8% below median
MedInfoBase company-intelligence methodology

This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.

Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.

Cite this record

Manufacturer record
MedInfoBase. (2026). Seraph Pharmaceutical — registered product portfolio in Pakistan [Data set]. MedInfoBase. Retrieved September 23, 2026, from https://medinfobase.com/company/seraph-pharmaceutical/
Download .RIS Download .BIB EndNote, Zotero, Mendeley, RefWorks

Records change over time. Please cite the access date so readers can locate the version you used.